The REDUCE HTN: REINFORCE
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVES The aim of this study was to investigate bipolar radiofrequency renal denervation in patients with hypertension not receiving medications at baseline. BACKGROUND A blood pressure-reducing effect of renal denervation has been difficult to isolate in clinical investigations. METHODS REDUCE HTN: REINFORCE (Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension) was a randomized, sham-controlled multicenter trial. Patients with office systolic blood pressure (SBP) of 150 to 180 mm Hg and average 24-h ambulatory SBP of 135 to 170 mm Hg after medication washout underwent bipolar radiofrequency renal denervation or a sham procedure. The planned outcome was 8-week change in 24-h ambulatory SBP. Enrollment was terminated for apparent futility before a sufficient sample for powered efficacy comparisons was enrolled. Safety assessments included all-cause death, renal failure, severe hypotension or syncope, hypertensive crisis, and renal artery stenosis. RESULTS Baseline 24-h blood pressure was 148.3 ± 10.9/85.7 ± 9.1 mm Hg for the denervation group (n = 34, mean age 58.5 ± 10.1 years, 47% women) and 149.1 ± 7.2/86.4 ± 9.8 mm Hg for the control group (n = 17, mean age 58.2 ± 9.8 years, 24% women). At 8 weeks, mean 24-h SBP reductions for the renal denervation and control groups were -5.3 mm Hg (95% confidence interval [CI]: -8.8 to -1.8 mm Hg) and -8.5 mm Hg (95% CI: -13.3 to -3.8 mm Hg), respectively (difference 3.3 mm Hg; 95% CI: -2.8 to 9.3 mm Hg; p = 0.30). Antihypertensive medications could then be added. By 6 months, decreases in SBP were greater for the denervation group, yielding between-group differences of -7.2 mm Hg (95% CI: -15.2 to 0.8 mm Hg; p = 0.08), -9.7 mm Hg (95% CI: -17.7 to -1.7 mm Hg; p = 0.02), and -11.4 mm Hg (95% CI: -19.2 to -3.7 mm Hg; p < 0.01) for 24-h, daytime ambulatory, and office measurements, respectively. Through 12 months, 1 patient (renal denervation group) had a hypertensive urgency requiring immediate management, and 1 experienced progression of renal artery stenosis. CONCLUSIONS Future studies of radiofrequency renal denervation must anticipate delayed treatment effects. (Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension [REDUCE HTN: REINFORCE]; NCT02392351).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Self-citationKrum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Azizi, M., Schmieder, R. E., Mahfoud, F., Weber, M. A., Daemen, J., Davies, J., Basile, J., Kirtane, A. J., Wang, Y., Lobo, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31082-1 · Cited by 740
Self-citationHering, D., Marusic, P., Walton, A. S., Lambert, E. A., Krum, H., Narkiewicz, K., Lambert, G. W., Esler, M. D., & Schlaich, M. P. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.03098 · Cited by 142
Renal Nerves and Long‐Term Control of Arterial Pressure
Osborn, J. W., & Foss, J. D. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c150047 · Cited by 93
Cited by
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
Böhm, M., Kario, K., Kandzari, D. E., Mahfoud, F., Weber, M. A., Schmieder, R. E., Tsioufis, K., Pocock, S., Konstantinidis, D., Choi, J. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30554-7 · Cited by 606
Self-citationMahfoud, F., Kandzari, D. E., Kario, K., Townsend, R. R., Weber, M. A., Schmieder, R. E., Tsioufis, K., Pocock, S., Dimitriadis, K., Choi, J. W., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00455-x · Cited by 295
Self-citationBarbato, E., Azizi, M., Schmieder, R. E., Lauder, L., Böhm, M., Brouwers, S., Bruno, R. M., Dudek, D., Kahan, T., Kandzari, D. E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad054 · Cited by 188
Ogoyama, Y., Tada, K., Abe, M., Nanto, S., Shibata, H., Mukoyama, M., Kai, H., Arima, H., & Kario, K. (2022) · Hypertension Research · doi:10.1038/s41440-021-00761-8 · Cited by 59
“FORCE trial [20] was not included in this subgroup analysis”
BackgroundMethod
Metadata
- Authors
- Weber, M. A., Kirtane, A. J., Weir, M. R., Radhakrishnan, J., Das, T., Berk, M., Mendelsohn, F., Bouchard, A., Larrain, G., Haase, M., Diaz-Cartelle, J., & Leon, M. B.
- Venue
- JACC: Cardiovascular Interventions
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 13
- Issue
- 4
- Pages
- 461-470
- ISSN
- 1876-7605 (ISSN-L)
- 1936-8798
- OpenAlex
- W3006471902
- Cited by
- 86
- References
- 5
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The REDUCE HTN: REINFORCE. https://app.cochat.ai/papers/10.1016/j.jcin.2019.10.061
- The paper
- Weber, M. A., Kirtane, A. J., Weir, M. R., Radhakrishnan, J., Das, T., Berk, M., Mendelsohn, F., Bouchard, A., Larrain, G., Haase, M., Diaz-Cartelle, J., & Leon, M. B. (2020). The REDUCE HTN: REINFORCE. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2019.10.061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.